Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

J Bayliss; L Yuen; G Rosenberg; D Wong; M Littlejohn; K Jackson; A Gaggar; KM Kitrinos; GM Subramanian; P Marcellin; M Buti; HLA Janssen; E Gane; V Sozzi; D Colledge; R Hammond; R Edwards; S Locarnini; A Thompson; PA Revill

Journal article

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

J Bayliss, L Yuen, G Rosenberg, D Wong, M Littlejohn, K Jackson, A Gaggar, KM Kitrinos, GM Subramanian, P Marcellin, M Buti, HLA Janssen, E Gane, V Sozzi, D Colledge, R Hammond, R Edwards, S Locarnini, A Thompson, PA Revill

Gut | BMJ PUBLISHING GROUP | Published : 2017

DOI: 10.1136/gutjnl-2015-309300

Abstract

Objective Hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss are important clinical outcomes for patients with chronic hepatitis B (CHB) treated with antiviral therapy. To date, there have been few studies that have evaluated viral sequence markers predicting serological response to nucleos(t)ide analogue (NA) treatment. Design We used next-generation sequencing (NGS) and quantitative HBV serology (HBeAg and HBsAg) to identify viral sequence markers associated with serological response to long-Term tenofovir disoproxil fumarate therapy among HBeAg-positive patients. In the GS-US-174-0103 study, approximately half the patients seroconverted to anti-HBe b..

View full abstract

University of Melbourne Researchers

Darren Wong Author

Margaret Littlejohn Author

Alexander Thompson Author

Peter Revill Author

Grants

Funding Acknowledgements

LY, JB, KJ, SB and PAR have received grant/research support from Gilead; AG, KMK and GMS are employees of and own stock in Gilead; SL is an advisor for Gilead and BMS; PM is an advisor for Abbott, Boehringer Ingelheim, BMS, Gilead, Janssen/Tibotec, Merck, Norvartis, Pfizer, Roche and Vertex; AT is an advisor for and has received grant/research support from Merck, Janssen/Tibotec, Gilead and Roche and speaker's fees from Merck, Roche and BMS. PAR is currently in receipt of a Royal Melbourne Hospital Keir Research Fellowship.